NasdaqGM - Nasdaq Real Time Price • USD
Ocular Therapeutix, Inc. (OCUL)
As of 12:32 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 7 |
| Avg. Estimate | -0.19 | -0.2 | -0.84 | -0.88 |
| Low Estimate | -0.31 | -0.43 | -1.93 | -1.71 |
| High Estimate | -0.14 | -0.13 | -0.51 | -0.39 |
| Year Ago EPS | -0.39 | -0.26 | -1.02 | -0.84 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 6 |
| Avg. Estimate | 15.41M | 16.38M | 68.34M | 85.9M |
| Low Estimate | 14.4M | 15.72M | 62.87M | 72.9M |
| High Estimate | 16.5M | 17.05M | 76M | 116M |
| Year Ago Sales | 13.37M | -- | 58.44M | 68.34M |
| Sales Growth (year/est) | 15.20% | -- | 16.90% | 25.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.26 | -0.3 | -0.29 | -0.3 |
| EPS Actual | -0.39 | -0.26 | -0.01 | -0.35 |
| Difference | -0.13 | 0.04 | 0.28 | -0.05 |
| Surprise % | -50.00% | 13.30% | 96.60% | -16.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.19 | -0.2 | -0.84 | -0.88 |
| 7 Days Ago | -0.19 | -0.2 | -0.83 | -0.88 |
| 30 Days Ago | -0.17 | -0.16 | -0.68 | -0.81 |
| 60 Days Ago | -0.21 | -0.22 | -0.94 | -0.82 |
| 90 Days Ago | -0.23 | -0.24 | -1 | -0.87 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 1 | -- |
Growth Estimates
| CURRENCY IN USD | OCUL | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 51.30% | -- | -- | 0.80% |
| Next Qtr. | 23.10% | -- | -- | 9.60% |
| Current Year | 17.60% | -- | -- | 4.50% |
| Next Year | -4.80% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/19/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 4/16/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 3/13/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/13/2024 |
| Maintains | TD Cowen: Market Perform to Market Perform | 3/12/2024 |
| Maintains | JMP Securities: Market Outperform to Market Outperform | 3/12/2024 |
Related Tickers
EYPT EyePoint Pharmaceuticals, Inc.
17.23
-1.57%
MREO Mereo BioPharma Group plc
2.5550
-3.58%
PDSB PDS Biotechnology Corporation
2.7550
-5.00%
CLRB Cellectar Biosciences, Inc.
3.0550
+0.49%
CYTK Cytokinetics, Incorporated
66.16
-1.25%
DAWN Day One Biopharmaceuticals, Inc.
15.03
-4.57%
CGEM Cullinan Therapeutics, Inc.
16.76
-7.20%
NMRA Neumora Therapeutics, Inc.
10.04
-4.88%
MDNAF Medicenna Therapeutics Corp.
1.2170
-1.85%
TGTX TG Therapeutics, Inc.
13.71
-2.04%